Skip to main content

RAD December 2022 Abstracts and Posters

All accepted abstracts have been published in The British Journal of Dermatology, Volume 188, Issue Supplement 2, February 2023. You may access the publication at:

#314 - Injection Site Reactions From an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials of Lebrikizumab Treatment in Moderate-to-Severe Atopic Dermatitis

Melinda Gooderham, Vivian Y Shi, Andreas Wollenberg, Jacob P. Thyssen, Tiago Torres, Esther Garcia Gil, Laia Bardolet, Chitra R. Natalie, Amber R. Atwater, Fangyi Zhao, Andrew Blauvelt

#315 - A Patient Survey to Identify Atopic Dermatitis Prescription Treatment Access Barriers

Allison R. Loiselle, PhD, Isabelle J.C.Thibau, MPH, Michele Guadalupe, MPH, Lisa Butler, MBA, Wendy Smith Begolka, MBS

#317 - Comparative Risk of Venous Thromboembolism (VTE) Among Patients With Atopic Dermatitis (AD) or Other Immune-mediated Diseases: A Cohort Study Using United States Claims Data

Joseph F. Merola, MD, MMSc; Raghava Danwada, MPH; Brennan Ertmer, PharmD; Huifang Liang, MD, PhD; Sarah Ofori, PharmD, MBA; Whitney Krueger, MPH, PhD

#318 - Facilitating Mentorship for Caregivers of Children with Atopic Dermatitis: The Supporting Eczema Caregivers Initiative

Michelle Tu, Lauren Amaro, Bennett Kidder, Keri Kelley, Korey Capozza, Alan Schwartz

#319 - Effects of omega-3 fatty acid supplementation on atopic dermatitis

Alyssa M Abdelnour, BS, Sarah J Shareef, BS, Kaitlin Kreuser, BS, Kurt Ashack, MD

#320 - Study Design and Interim Recruitment into the Post-authorization Safety Study to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy in North America

Diana L. Johnson, Ronghui Xu, Yunjun Luo Y, Kenneth Lyons Jones, Christina D. Chambers, and the OTIS Collaborative Research Group

#321 - Cancer Risk with Topical Pimecrolimus and Tacrolimus for Atopic Dermatitis: Systematic Review and Bayesian Meta-Analysis

Alexandro, W L, Chu, Niveditha, Devasenapathy, Melanie, Wong, Archita, Srivastava, Renata, Ceccacci, Clement, Lin, Margaret, MacDonald, Aaron, Wen, Jeremy, Steen, Mitchell, Levine, Lonnie, Pyne, Julie, Wang, Jonathan, M, Spergel, Jonathan, I, Silverberg, Peck, Y, Ong, Monica, O’Brien, Stephan, A, Martin, Peter, A, Lio, Mary Laura, Lind, Jennifer, LeBovidge, Elaine, Kim, Joey, Huynh, Matthew, Greenhawt, Winfred, T, Frazier, Lina, Chen, Anna, De Benedetto, Mark, Boguniewicz, Rachel, N, Asiniwasis, Lynda, Schneider, Derek, K, Chu

#322 - Efficacy And Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)

Andrew Blauvelt1, Jacob P. Thyssen2, Emma Guttman-Yassky3, Thomas Bieber4, Jose Manuel Carrascosa5, Eric Simpson6, David Rosmarin7, Hany Elmaraghy8, Eric Meskimen8, Chitra R Natalie8, Zhuqing Liu8, Chenjia Xu8, Evangeline Pierce8, MaryAnn Morgan-Cox8, and Jonathan I. Silverberg9

#323 - Onset of Atopic Comorbidities Relative to Atopic Dermatitis Diagnosis in a Real-World Setting Using an Israeli Claims Database

Yael Leshem, Allan Becker, William W. Busse, Lisa A. Beck, Clara Weil, Moataz Daoud, Robert Lubwama

#324 - Tralokinumab provides progressive and sustained efficacy in adolescents with moderate-to-severe atopic dermatitis: a post-hoc analysis of the ECZTRA 6 trial

Eric L Simpson, Andreas Wollenberg, Azra Kurbasic, Ann-Marie Tindberg, Lise Soldbro, Amy S. Paller

Page 2 of 5
Results 11 - 20 of 50